Case guide

Which Depo-Provera Shot Did I Get, and Who Made It?

Not sure which shot you received? Gather the product and clinic records.

See If You Qualify

Free · No obligation · About 2 minutes

Updated Oct 4, 202616 sources

This may apply to you if

  • Have your shot name and dates ready for a lawyer to review.
  • Have the report that names your meningioma, a tumor in tissue around the brain.
  • If you already have a lawyer, ask whether your claim is eligible for the reported program.

What the public record says

These are cited sources. Their inclusion does not imply that they endorse People’s Justice or reviewed this page.

M. Casey Rodgers · U.S. District Court, Northern District of Florida · United States District Judge

Finding: The August 10, 2026 order describes an agreement for many existing federal claims and separate court procedures for continuing litigation. Ask a lawyer which track applies to you.

Case Management Order No. 14 (opens in a new tab) · Aug 10, 2026 · Checked Oct 3, 2026

Noémie Roland · EPI-PHARE, French National Agency for Medicines and Health Products Safety and French National Health Insurance · First-listed study author

Finding: The 2024 BMJ study found an association between injectable medroxyprogesterone use and meningioma surgery in French health records. A small exposed group and observational design limit what it can show about an individual.

Use of progestogens and the risk of intracranial meningioma: national case-control study (opens in a new tab) · Mar 27, 2024 · Checked Oct 3, 2026

The evidence and its limits

EPI-PHARE · BMJ · 2024

French health-record study of hormone medicines and meningioma surgery

Design:
Case-control
Participants:
108,366 women: 18,061 surgery cases and 90,305 matched controls
Finding:
Injectable medroxyprogesterone acetate use was associated with higher odds of surgery for meningioma; the excess was linked to prolonged use.
Main limitation
Observational French data; only nine exposed cases and eleven exposed controls for this injection. The study does not prove that the shot caused any one person’s tumor or define who qualifies for a claim.

Read the source: French health-record study of hormone medicines and meningioma surgery (opens in a new tab) · Checked Oct 3, 2026

The short answer

Why does the exact product matter?
The order names the brand and certain versions sold without that brand name. Show your lawyer the name in your records. Say if you cannot confirm it. [1]
Are Pfizer and every generic company in the same program?
Do not assume so. The court notice names certain companies and existing cases. Ask which company and program your own case involves. [1]
What can the clinic record help me check?
Ask for the name, date and dose recorded for each shot. If a record is missing, note the gap. Keep original copies rather than rewriting a guessed history. [6]
Does the warning prove the company caused my tumor?
No. The label warns about tumors after repeat use. It does not tell us what caused your own tumor. [3]

What rules a case out

Not covered by this case

  • A company name does not establish an individual product-use history.
  • A court allegation does not decide personal tumor causation.
  • A settlement announcement does not cover every user by itself.

The process

What happens next

  1. 01

    You answer a few questions

    About two minutes. Nothing is sent until you agree on the last step and press submit.

  2. 02

    A lawyer looks at it

    A lawyer at the firm reads your answers and checks them against the current case criteria.

  3. 03

    The firm decides and gets in touch

    If the firm takes your case, you get the terms in writing to read before you sign. You can always say no.

Not sure which shot you received? Gather the product and clinic records. Ask a lawyer to check the named product before treating a company name as proof.

Why does the exact product matter?

The order names the brand and certain versions sold without that brand name. Show your lawyer the name in your records. Say if you cannot confirm it.

The order names Depo-Provera, Depo-SubQ Provera 104 and certain unbranded versions within its stated product scope. That list does not prove which product your clinic used. Ask for the medication administration record or other use documents.

Are Pfizer and every generic company in the same program?

Do not assume so. The court notice names certain companies and existing cases. Ask which company and program your own case involves.

The August 10, 2026 order reports a July 22 agreement involving Pfizer, Pharmacia and Pharmacia & Upjohn. It also describes claims that continue in court. Read the actual terms with your lawyer instead of using a company headline as an eligibility rule.

What can the clinic record help me check?

Ask for the name, date and dose recorded for each shot. If a record is missing, note the gap. Keep original copies rather than rewriting a guessed history.

An individual generally has an access route for covered health records, with exceptions. Ask the provider about its request process and which records it still maintains. A current package label cannot reconstruct a clinic visit from years ago.

Does the warning prove the company caused my tumor?

No. The label warns about tumors after repeat use. It does not tell us what caused your own tumor.

The original French study found an association with injectable medroxyprogesterone and meningioma surgery. It did not assign an individual tumor to a company being sued or decide a lawsuit. The exposed injection groups were small.

If you have a diagnosis, discuss the label with your clinician. Ask your lawyer separately what product identity and causal evidence the claim requires.

What should I bring to a product-identity review?

Bring clinic records and tumor reports if you have them. List dates and treatment sites. Ask which records are still needed.

Ask whether an existing lawyer engagement or case changes the available route. The administrative program cutoff in the order is not a universal rule that all later inquiries are barred. Personal legal deadlines require their own review.

Ask which firm would handle the case and how fees and expenses work. A public manufacturer page is not proof that a lawyer has accepted your claim.

Scientific evidence for this case

Find out where you stand.

The review is free and private. Asking for it doesn’t commit you to anything.

Register your interest

Questions about this guide

How big is Pfizer?

While Depo-Provera is not Pfizer's largest product, the company's deep pockets mean it has the ability to pay substantial settlements. Pfizer's corporate conduct — prioritizing revenue over timely label updates — is central to punitive damages arguments.

Can Pfizer argue the FDA rejected their label change attempt?

Pfizer may try to argue it attempted to update the label in 2024 but was rejected by the FDA. However, this defense is weakened by several factors: Pfizer could have voluntarily added the warning through the CBE pathway without prior FDA approval, Canada warned in 2015 (9 years earlier), and the science linking progestins to meningioma dates to the 1980s. Pfizer's first label attempt in 2024 came only after the French BMJ study generated widespread media attention.

What about generic Depo-Provera manufacturers?

Generic manufacturers of MPA injectable contraceptive are also defendants in the MDL, including A-S Medication Solutions, Greenstone LLC (a Pfizer subsidiary), Prasco Laboratories, Pharmacia & Upjohn Company LLC, Preferred Pharmaceuticals Inc., and Viatris. If you used a generic version, you may have claims against the generic manufacturer.

Sources

  1. Court order 14: settlement and ongoing casesCourt order 14: settlement and ongoing cases · court
  2. JPML pending cases report, October 1, 2026JPML pending cases report, October 1, 2026 · court
  3. FDA Depo-Provera CI label, December 2025FDA Depo-Provera CI label, December 2025 · regulator
  4. National Cancer Institute: meningiomaNational Cancer Institute: meningioma · regulator
  5. ABA Model Rule 1.5: feesABA Model Rule 1.5: fees
  6. Medical record access: 45 CFR 164.524Medical record access: 45 CFR 164.524 · regulator
  7. SDNY court guide: filing time limitsSDNY court guide: filing time limits · court
  8. Court common-benefit fee order 2Court common-benefit fee order 2 · court
  9. BMJ 2024 original author abstract via PubMedBMJ 2024 original author abstract via PubMed · study
  10. Medroxyprogesterone Acetate and Meningioma: A Global IssueFrontiers in Global Womens Health · 2025 · study
  11. Use of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial MeningiomaThe BMJ · 2024 · study
  12. The Association between Medroxyprogesterone Acetate Exposure and MeningiomaCancers · 2024 · study
  13. Pfizer Reaches Agreement in Principle to Resolve Federal Depo-Provera MDLlaw360.com · Jun 15, 2026 · court
  14. JAMA Network Open Study Reports 4.5x Meningioma Risk with Medroxyprogesteronepubmed.ncbi.nlm.nih.gov · Jul 1, 2026 · study
  15. On June 15, 2026, MDL 3140 (N.D. Fla.) Leadership Counsel announced a settlement with the Pfizer defendants of a majority of the claims in the MDL and New York state court over Depo-Provera meningioma claims (Case Management Order No. 12, filed July 27, 2026). Financial terms NOT disclosed; eligibility and compensation amounts not released; deal pending finalization at the time (Case Management Order No. 14, filed Aug. 10, 2026, later described a settlement agreement dated July 22, 2026 and states no compensation amounts). The JPML reported 5,830 actions pending in MDL 3140 on July 1, 2026 and 6,412 on October 1, 2026.flnd.uscourts.gov · Jun 15, 2026 · court
  16. Settlement in principle announced; docket had grown +1,739 filings (+46%) in the single preceding month — the leading-indicator pattern.jpml.uscourts.gov · Jun 15, 2026 · court

Checked against 14 primary sources by People's Justice editors · Updated

How we make money

People's Justice research team · Updated Oct 4, 2026